ERBB2 and breast cancer: To accomplish this, we undertook a prospective study from May/2016 to June/2019 of 50 consecutive pre and postmenopausal patients with metastatic HR+/HER2-negative BC treated as per standard practice with CDK4/6i and ET (Fig. 1a).